Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • Bitcoin USD

    63,817.95
    -839.29 (-1.30%)
     
  • CMC Crypto 200

    1,329.45
    -67.08 (-4.80%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • Dow

    38,239.66
    +153.86 (+0.40%)
     
  • Nasdaq

    15,927.90
    +316.14 (+2.03%)
     
  • Gold

    2,349.60
    +7.10 (+0.30%)
     
  • Crude Oil

    83.66
    +0.09 (+0.11%)
     
  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Sanofi chairman says acquisitions not 'indispensable' for future

French drugs firm Sanofi's logo is pictured inside the company's headquarters during the company's 2014 annual results presentation in Paris February 5, 2015. REUTERS/Charles Platiau

PARIS (Reuters) - French pharmaceutical company Sanofi (SASY.PA) has examined acquisitions opportunities but does not view deal-making as "indispensable" to its future, its chairman told French paper Les Echos in an interview.

"We looked at potential deals but found the asking prices to be too high for the businesses," said Sanofi Chairman Serge Weinberg.

"We have opted for a balanced a strategy of innovation and diversification that makes acquisitions not indispensable."

The global pharmaceutical industry has been consolidating in recent years as companies seek to replace drugs that are losing patent protection and renew their pipeline with new products.

ADVERTISEMENT

Through early March, M&A transactions targeting biotech and pharma companies reached $59.3 billion this year, a 94 percent increase over the same period a year ago and the highest volume for this stage in any year since 2009.

(Reporting by Leila Abboud; Editing by Miral Fahmy)